A 36-week treatment regimen of pegcetacoplan reduces geographic atrophy growth rate while demonstrating a favorable safety profile.

Operator Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator ...

Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to ...

The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information ...

The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com. About Peak Bio, Inc. Peak Bio (OTC: ...

That’s why National Geographic and Rolex have partnered to support trailblazing scientific research, expeditions, and solutions to increase our understanding of the threats facing the planet’s ...